Most of the ongoing immunotherapy clinical trials in meningiomas are focused on targeting the programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) axis, such as NCT03173950, NCT03016091, and NCT03279692. Here, CD274 is linked to meningioma.